The role of LncRNAs in tumor immunotherapy

Cancer Cell International

Review

Jifeng Feng¹  Chenchen Li¹  Xuan Pan¹ 

[1] Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People’s Republic of China;

关键词: LncRNAs;    Tumor immunotherapy;    PD-1;    PD-L1;    CTLA-4;    TIM-3;   

DOI  :  10.1186/s12935-023-02872-3

 received in 2022-12-13, accepted in 2023-02-13,  发布年份 2023

来源: Springer

【 摘 要 】

Cancer immunotherapy is a major breakthrough in the history of tumor therapy in the last decade. Immune checkpoint inhibitors blocking CTLA-4/B7 or PD-1/PD-L1 pathways have greatly prolonged the survival of patients with different cancers. Long non-coding RNAs (lncRNAs) are abnormally expressed in tumors and play an important role in tumor immunotherapy through immune regulation and immunotherapy resistance. In this review, we summarized the mechanisms of lncRNAs in regulating gene expression and well-studied immune checkpoint pathways. The crucial regulatory function of immune-related lncRNAs in cancer immunotherapy was also described. Further understanding of the underlying mechanisms of these lncRNAs is of great importance to the development of taking lncRNAs as novel biomarkers and therapeutic targets for immunotherapy.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

42004_2023_830_Article_IEq36.gif

Fig. 2

Fig. 5

40854_2023_458_Article_IEq52.gif